Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2020

View Archived Issues

Enrollment completed and interim data presented from DRIIV-1b study of AsiDNA

Kira secures investments to advance development of novel complement-targeted therapies

Curasight initiates preclinical study of uTREAT therapy in brain cancer

First patient treated in phase I study of MaaT-033

Medshine Discovery divulges KLKB1 inhibitors

HitGen patents HDAC inhibitors

Enrollment completed in phase III study of Covishield in India

Epitas Biosciences presents IDH2 inhibitors

Betta Pharmaceuticals synthesizes new KRAS mutant inhibitors

Shanghai Public Utilities Institute patents antibodies for SARS-CoV-2 infection

Sharing without oversharing: Quick-ish cleanup can preserve privacy in functional genomics datasets

Safety, pharmacology and preliminary efficacy of VT-1021 in patients with advanced solid tumors

First patient dosed in phase II study of tomivosertib plus chemotherapy in breast cancer

FDA allows IND application for AV-001 in hospitalized patients with COVID-19

BVX-0320 vaccine candidate shows promising preclinical efficacy against SARS-CoV-2

[124I]-RmAb158-scFv8D3 detects soluble Abeta changes following treatment

Selva begins phase I study with SLV-213 to treat COVID-19

Navidea reports further phase IIb data on Tc99m tilmanocept imaging for rheumatoid arthritis

Verrica reports phase II topline data on VP-102 for external genital warts

Denali achieves biomarker proof of concept for transport vehicle technology with DNL-310

Medicago's adjuvanted COVID-19 vaccine candidate advances into phase II/III

Trinomab cleared to begin phase I study in Australia with anti-tetanus toxin monoclonal antibody

Orchard presents new HSC gene therapy research programs in dementia and Crohn's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...